PDL BioPharma to Announce 2019 Fourth Quarter and Full Year Financial Results on March 11, 2020

March 4, 2020 |

2 min read

PDL BioPharma, Inc. (“PDL” or “the Company”) (Nasdaq: PDLI) announces that it will release its 2019 fourth quarter and full year financial results for the period ended December 31, 2019 , on Wednesday, March 11, 2020 , after market close.

INCLINE VILLAGE, Nev., March 4, 2020 /PRNewswire/ -- PDL BioPharma Inc, Inc. ("PDL" or "the Company") (Nasdaq: PDLI) announces that it will release its 2019 fourth quarter and full year financial results for the period ended December 31, 2019, on Wednesday, March 11, 2020, after market close. PDL's management will host a conference call and webcast that day at 4:30 p.m. Eastern time to discuss the operating and financial results and recent developments. A slide presentation relating to the call will be available via the webcast link on the PDL website at http://www.pdl.com/.

Conference Call Details
To access the live conference call via phone, please dial (844) 535-4071 from the United States and Canada or (706) 679-2458 internationally. The conference ID is 8017938. Please dial in approximately 10 minutes prior to the start of the call. A telephone replay will be available for one week following the call and may be accessed by dialing (855) 859-2056 from the United States and Canada or (404) 537-3406 internationally. The replay passcode is 8017938.

To access the live and subsequently archived webcast of the conference call, go to the Company's website and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.

About PDL BioPharma
Throughout its history, PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies. PDL BioPharma was founded in 1986 as Protein Design Labs, Inc. when it pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of targeted treatments that have had a profound impact on patients living with different cancers as well as a variety of other debilitating diseases. In 2006, the Company changed its name to PDL BioPharma, Inc.

As of December 2019, PDL ceased making additional strategic transactions and investments and is pursuing a formal process to unlock the value of its portfolio by monetizing its assets and ultimately distributing net proceeds to shareholders.

For more information please visit https://www.pdl.com/.

NOTE: PDL, PDL BioPharma, the PDL logo and associated logos and the PDL BioPharma logo are trademarks or registered trademarks of, and are proprietary to, PDL BioPharma, Inc. which reserves all rights therein.

PDL BioPharma, Inc. (PRNewsFoto/PDL BioPharma, Inc.)